# MOTS-c: Research Overview — Peptide Research Protocols > A literature summary of MOTS-c, a mitochondrial-derived peptide studied for AMPK activation, skeletal-muscle glucose handling and physical performance — mechanism, animal evidence, and regulatory status. Sixteen amino acids written not in the nuclear genome but in the mitochondrial DNA — studied as an AMPK activator and exercise-mimetic, almost entirely in animal models. ## The short version MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is unusual in a fundamental way: it is encoded not in the chromosomes in the cell nucleus but inside a tiny piece of DNA that lives in mitochondria — the organelles that produce cellular energy. That origin means it is a *mitochondrial-derived peptide*, or MDP, a category that barely existed in the scientific literature before 2015. The peptide is 16 amino acids long (MRWQEMGYIFYPRKLR). Its best-characterised action is to activate AMPK, a master metabolic switch, by interfering with the folate cycle inside cells — which improves glucose handling primarily in skeletal muscle [10]. In animal studies it increases physical performance in young, middle-aged and aged mice [11], and a 2024 study identified casein kinase 2 (CK2) as a direct molecular target [8]. The honest limit: almost all of this is in animals. The only published human data are biomarker associations in a haemodialysis patient cohort, not an intervention trial [9]. MOTS-c is not approved anywhere, it is treated as a prohibited substance in elite sport, and this page lists no human dose. ## What it is MOTS-c is a 16-amino-acid peptide, sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA gene (MT-RNR1). It is highly conserved across mammalian species — an indicator that the sequence performs a functionally important role preserved through evolution. It belongs to a small and recently characterised family of mitochondrial-derived peptides (MDPs), which also includes humanin and SHLP1-6. What makes MDPs notable is that they are secreted from the mitochondrion and act as signalling molecules affecting the rest of the cell — and in MOTS-c's case, the rest of the body. The fact that they are mitochondrially encoded makes them candidates for explaining some of the health associations tied to mitochondrial genetics, including ancestry-dependent variations in metabolic traits [10]. ## How it works MOTS-c's best-characterised mechanism involves the folate cycle and purine biosynthesis. By inhibiting the enzyme MTHFD1L in the folate cycle, MOTS-c reduces de novo purine synthesis. This causes a build-up of an intermediate called AICAR, which in turn activates *AMP-activated protein kinase* (AMPK). AMPK is a central metabolic regulator: when it is activated, cells increase glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis. The net effect, demonstrated primarily in skeletal muscle, is improved glucose handling and insulin sensitivity [10]. Under metabolic stress a second, distinct action is observed: MOTS-c translocates from the mitochondrion to the nucleus, where it regulates nuclear gene expression in an AMPK-dependent manner, including genes in the antioxidant-response-element (ARE) pathway through interaction with NRF2 — the first demonstration of retrograde signalling by a mitochondrially encoded peptide [12]. A 2024 study added precision to this picture: MOTS-c was shown to directly bind and activate casein kinase 2 (CK2). Tissue-specific CK2 modulation — activation in muscle, suppression in fat — underlies MOTS-c's effects on muscle glucose uptake and its prevention of skeletal-muscle atrophy [8]. ## What the research shows *CK2 as direct target.* In cell-free assays, MOTS-c directly bound and activated CK2; in mice (young, aged, high-fat-diet and immobilised), this resulted in prevention of skeletal-muscle atrophy and enhanced muscle glucose uptake through tissue-specific CK2 modulation. This is the most molecularly precise finding for MOTS-c to date [8]. *Physical performance in mice.* Exercise induces endogenous MOTS-c expression in skeletal muscle and circulation. Exogenous MOTS-c significantly enhanced treadmill running capacity, grip strength and gait in young (2 months), middle-aged (12 months) and aged (22-23.5 months) mice — with the most striking effects in the oldest animals, where the improvement was highly significant (P=0.000002). This positions MOTS-c as an exercise-mimetic and regulator of age-dependent physical decline [11]. *Nuclear translocation.* Under metabolic stress, MOTS-c translocates to the nucleus and regulates ARE/antioxidant and metabolic gene expression through AMPK and NRF2, establishing a mitochondria-to-nucleus communication loop [12]. *Mechanistic synthesis.* A 2023 comprehensive review consolidated MOTS-c's encoding within MT-RNR1, its AMPK/folate-cycle mechanism, nuclear translocation, exercise-inducibility, and roles in metabolic, stress-adaptive and aging pathways — the modern framework for understanding the peptide [10]. *Human biomarker association.* In a prospective multicenter cohort of 94 chronic haemodialysis patients with a median 26.5-month follow-up, circulating MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05), and adding MOTS-c improved risk-model discrimination (ROC AUC 0.727 to 0.743) [9]. This is observational data, not an intervention trial — the strongest available human signal but not efficacy evidence. ## Reported effects, cautions and safety MOTS-c occupies the most preliminary position in human evidence on this desk. Several specific cautions apply: - *No human efficacy trials.* Every claim about exogenous MOTS-c improving metabolism, performance or aging derives from cell culture or animal studies (predominantly mice and rats). Human data are observational biomarker associations, not interventional outcomes [9]. - *No validated human pharmacokinetics.* There is no published measured human half-life, bioavailability or dose-response for exogenous MOTS-c. Rodent doses studied (0.5–15 mg/kg/day) cannot be extrapolated to humans [10]. - *Research-chemical status.* MOTS-c is not approved by any regulator and is sold only for laboratory research; product purity, identity and sterility vary by supplier and are not regulated as pharmaceuticals. - *Anti-doping prohibition.* Anti-doping bodies (USADA/WADA) classify MOTS-c among peptide and metabolic-modulator agents prohibited at all times; athlete use can result in sanctions. - *Ancestry and genotype interactions.* A pro-diabetogenic MOTS-c mtDNA variant (m.1382A>C) and ancestry-dependent differences in exercise responses suggest that effects are not uniform across populations [10]. - *Marketplace claims outpace evidence.* Consumer interest in fat loss, longevity and performance substantially exceeds the strength of the current clinical evidence, and this desk exists specifically to contextualise that gap. No community-anecdote reports are compiled in this desk's source material for MOTS-c, so none are presented; the points above are drawn from the cited literature. ## Where it fits in GH axis research MOTS-c is the most mechanistically novel compound on this desk. Where [tesamorelin](/tesamorelin) operates at the level of pituitary receptor signalling and [CJC-1295](/cjc-1295) is an engineered GHRH analogue extending that signal, MOTS-c works at the cellular metabolic machinery — inside mitochondria and at the AMPK node that coordinates energy use across tissues. Its connection to the GH/IGF-1 theme is metabolic overlap: AMPK-driven improvements in glucose handling and insulin sensitivity sit in the same functional space as the downstream effects of GH-axis activation, even though the molecular entry point is entirely different. The animal exercise and anti-atrophy data are compelling as a research direction; what is missing is any controlled human interventional work. See how it compares on the [comparison page](/compare). ![MOTS-c mitochondrial origin and nuclear translocation motif in cold plum and magenta](/images/mots-c.webp) --- Peer-reviewed literature on GH axis peptides, summarised without dosing guidance, clinical claims, or products.